None listed
Conditions
Interventions
Drug : Patients with hepatocellular carcinoma were randomly assigned to 1: 1 carotid artery chemoembolization. The dexamethasone group received intravenous dexamethasone 15 mg and ramoxetron 0.3 mg on
Sponsors
Chonnam National University Hospital Hwasun Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - A patient who was diagnosed with hepatocellular carcinoma in Chonnam National University Hospital, Chosun University Hospital, and Kwangju Christian Hospital and who had undergone carotid embolization. - Diagnosis of hepatocellular carcinoma: Findings of 1 cm or more found in high risk hepatocellular carcinoma (liver cirrhosis, chronic hepatitis B, chronic hepatitis C with advanced fibrosis or liver cirrhosis) A) Typical imaging findings (arteriovenous enhancement and portal or delayed clearing phenomenon) on dynamic contrast enhanced CT or dynamic contrast enhanced MRI In the case of nodules with no typical imaging findings, secondary imaging findings (moderate signal intensity on MRI T2-weighted images, high signal intensity on diffusion-weighted images, low signal intensity on BACs, Mosaic pattern, nodule within the nodule, fat in the mass, or bleeding) is appropriate - age 18 or older - Persons with liver function preserved - Carotid embolization using Doxorubicin - Those with serum creatinine less than 1.5 mg / dL
Exclusion criteria
Exclusion criteria: - Those who did not agree with the study - Those under 18 years of age - Those with underlying diseases such as cancer of other organs other than liver cancer, advanced heart disease, advanced renal disease - Carotid artery embolization, hepatectomy or systemic chemotherapy - Those with a grade 1 or higher fever, anorexia, nausea / vomiting, etc. at the base - Those with active bacterial infection (who have been treated with antibiotics within 1 week of diagnosis) - Those with human immunodeficiency virus (HIV) infection - Those with uncontrolled diabetes (HbA1c = 8.0g / dL) - Those with autoimmune hepatitis - Those who are positive for HBV DNA but do not take hepatitis B drugs (antiviral drugs) - Those with extrahepatic or microvascular involvement - Those who were taking steroids or anti-inflammatory drugs at random. Those who have hypersensitivity to -COX2-inhibitors - Gastrointestinal bleeding diagnosed or suspected
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-embolism syndrome (fever after CTCAE grade 1 or higher, abdominal pain, nausea / vomiting, poor appetite) | — |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence of a condition that does not receive rehospitalization or tumor treatment due to complications within 12 weeks after the procedure | — |
Countries
Korea, Republic of
Contacts
Public ContactMin Woo Chung
Chonnam National University Hospital Hwasun Hospital
Outcome results
None listed